Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to significant losses suffered by investors following misleading statements regarding the safety of its clinical trial for RP-A501 [2][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is encouraging investors who incurred losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2]. - The firm has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations Against Rocket Pharmaceuticals - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. - It was revealed that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing securities at inflated prices [4]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event, including death, which was not disclosed to investors prior to the incident [5]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Group 1 - The core issue involves a class action lawsuit against Rocket Pharmaceuticals, alleging violations of the Securities Exchange Act of 1934 related to misleading statements about the safety and clinical trial protocol of its gene therapy product RP-A501 [1][4][5] - The lawsuit claims that Rocket Pharmaceuticals failed to disclose serious adverse events, including patient deaths, during a Phase 2 clinical trial for Danon disease, which led to a significant drop in the company's stock price following the FDA's clinical hold announcement [4][5] - Investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, are eligible to seek appointment as lead plaintiff in the class action lawsuit [1][6] Group 2 - Rocket Pharmaceuticals is characterized as a late-stage biotechnology company focused on developing gene therapies for rare diseases [3] - The law firm Robbins Geller Rudman & Dowd LLP, known for its expertise in securities fraud litigation, is representing the investors in this class action case [7]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and the clinical trial protocol, including the risk of Serious Adverse Events (SAEs) [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of a clinical hold by the FDA due to a SAE, including a participant's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's status through a portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price after the FDA placed a clinical hold on the study following a Serious Adverse Event [2][3]. Group 1: Allegations and Events - The lawsuit claims that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths [2]. - The company amended the clinical trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [2]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [2]. Group 2: Shareholder Actions - Shareholders who purchased RCKT shares during the class period from February 27, 2025, to May 26, 2025, are encouraged to register for the class action and may seek lead plaintiff status by the deadline of August 11, 2025 [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [3]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements or omissions by companies [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Rocket Pharmaceuticals [3]. - The complaint alleges that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [5]. Group 2: Clinical Trial Issues - Rocket Pharmaceuticals faced a clinical hold from the FDA on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), which ultimately resulted in death [6]. - The company amended the trial protocol to introduce a new immunomodulatory agent without disclosing this critical update to investors, which is a key point of contention in the lawsuit [5][6]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the upcoming lead plaintiff deadline on August 11, 2025 [1] Group 1: Class Action Details - Investors who purchased Rocket Pharmaceuticals securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 11, 2025 [3] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that Rocket Pharmaceuticals provided misleading statements regarding the safety and clinical trial protocol of RP-A501, concealing material adverse facts, including the risk of Serious Adverse Events (SAEs) [5] - It is claimed that the company amended the trial's protocol without informing shareholders, leading to artificially inflated stock prices [5]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading information regarding its clinical trials, particularly concerning the safety of its gene therapy product RP-A501 for Danon disease [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals and a top executive violated the Securities Exchange Act of 1934 by concealing material adverse facts about the safety and clinical trial protocol of RP-A501 [3]. - It is claimed that the company failed to disclose serious adverse events, including the death of a participant, which occurred after a protocol amendment that introduced a new immunomodulatory agent [3][4]. Group 2: Impact on Stock - Following the announcement of a clinical hold by the U.S. Food and Drug Administration on May 27, 2025, due to a serious adverse event, Rocket Pharmaceuticals' stock price experienced a decline [4]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [5]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating its strong track record in obtaining monetary relief for investors [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses following a serious adverse event [2][4][5]. Group 1: Company Overview - Rocket Pharmaceuticals, Inc. is a publicly traded company on NASDAQ under the ticker RCKT [2]. - The company has faced legal scrutiny following a clinical hold placed by the FDA on its RP-A501 Phase 2 pivotal study due to serious adverse events, including a participant's death [5]. Group 2: Legal Proceedings - A federal securities class action has been filed against Rocket Pharmaceuticals, with a deadline of August 11, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that Rocket provided overly positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [4]. Group 3: Financial Impact - Following the announcement of the FDA's clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [6].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in a significant drop in stock price following the announcement of a clinical hold by the FDA [3][4]. Summary by Sections Allegations - The complaint alleges that Rocket Pharmaceuticals provided overly positive statements while concealing material adverse facts about RP-A501's safety, including the risk of Serious Adverse Events (SAEs) and participant deaths during the clinical trial [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. Stock Price Impact - Following the announcement of the FDA's clinical hold on May 27, 2025, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share, marking a decline of approximately 37% in just one trading day [3]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action, with a deadline of August 11, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [5].

Core Viewpoint - Investors in Rocket Pharmaceuticals, Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred [1][2]. Group 1: Lawsuit Details - The lawsuit alleges that from February 27, 2025, to May 26, 2025, Rocket Pharmaceuticals failed to disclose significant risks, including serious adverse events (SAEs) such as participant deaths in clinical studies [3]. - The complaint states that Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to misleading positive statements about the company's operations and prospects [3]. Group 2: Participation Information - Investors who suffered losses in Rocket Pharmaceuticals are encouraged to contact the Law Offices of Howard G. Smith before August 11, 2025, to participate in the ongoing lawsuit [2][4]. - Individuals interested in learning more about the class action or their rights can reach out to the law firm via email or phone [4][5].